aTyr Pharma (ATYR) SEC Filings: History & Chart

aTyr Pharma, Inc.(ATYR)

Biotechnology · San Diego, CA

$0.29+0.00 (+0.97%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About aTyr Pharma, Inc.

aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.

San Diego, CA

58 employees

www.atyrpharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Sanjay S. Shukla

View full financials

Form	Filing Date	Accepted	Document
4	Oct 1, 2026	Oct 1, 2026	View filing
3	Oct 1, 2026	Oct 1, 2026	View filing
8-K	Sep 24, 2026	Sep 24, 2026	View filing
DEF 14A	Sep 11, 2026	Sep 11, 2026	View filing
PRE 14A	Aug 31, 2026	Aug 31, 2026	View filing
S-8	Aug 7, 2026	Aug 7, 2026	View filing
10-Q	Aug 7, 2026	Aug 7, 2026	View filing
8-K	Aug 7, 2026	Aug 7, 2026	View filing
SC 13G/A	Aug 6, 2026	Aug 6, 2026	View filing
8-K	Jul 31, 2026	Jul 31, 2026	View filing
SC 13G/A	Jul 27, 2026	Jul 27, 2026	View filing
SC 13G/A	Jul 8, 2026	Jul 8, 2026	View filing
8-K	Jun 8, 2026	Jun 8, 2026	View filing
SC 13G/A	Jun 5, 2026	Jun 5, 2026	View filing
8-K	Jun 1, 2026	Jun 1, 2026	View filing
4	May 28, 2026	May 28, 2026	View filing
10-Q	May 15, 2026	May 15, 2026	View filing
8-K	May 15, 2026	May 15, 2026	View filing
4	May 13, 2026	May 13, 2026	View filing
4	May 13, 2026	May 13, 2026	View filing
4	May 13, 2026	May 13, 2026	View filing
4	May 13, 2026	May 13, 2026	View filing
4	May 13, 2026	May 13, 2026	View filing
4	May 13, 2026	May 13, 2026	View filing
8-K	May 11, 2026	May 11, 2026	View filing
ARS	Mar 26, 2026	Mar 26, 2026	View filing
DEFA14A	Mar 26, 2026	Mar 26, 2026	View filing
SC 13G/A	Mar 26, 2026	Mar 26, 2026	View filing
DEF 14A	Mar 26, 2026	Mar 26, 2026	View filing
PRE 14A	Mar 12, 2026	Mar 12, 2026	View filing

SEC Filings

Recent Filings